Study guide
7.3 Consent Documentation, Special Circumstances and Updates
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
7.3 Consent Documentation, Special Circumstances and Updates
Key Takeaways Explain This Topic AI
Paper or electronic signed and dated consent can be appropriate under the approved process.
An impartial witness is needed for the applicable unable-to-read consent process.
New information affecting willingness to continue should be communicated in a timely way.
Last updated: October 2026
Consent Documentation, Special Circumstances and Updates
When a participant (or LAR) is unable to read or write:
An impartial witness (an individual independent of the trial, who cannot be unfairly influenced by people involved with the trial) must be present during the entire informed consent discussion.
The written ICF and any other written information is read aloud and explained to the subject.
The subject orally consents and, if physically able, signs or makes their mark (e.g., a thumbprint) on the ICF.
The impartial witness must personally sign and date the consent form, attesting that the information in the ICF was accurately explained to, and apparently understood by, the subject, and that consent was freely given.
The person obtaining consent also personally signs and dates the document.
Language, capacity and electronic approaches
Use consent materials and discussion understandable to the participant. Plan appropriate translation and interpreter support; verify the approved language/version and any required certification. The ECO includes a task to facilitate and verify certification of translations. Back-translation is a possible quality method, not a universal ICH requirement. A witness for inability to read is distinct from an interpreter for a language difference.
Where a minor is enrolled, provide age-appropriate information and seek assent as appropriate under the reviewed process and applicable requirements. The number of parents whose permission is needed depends on local rules and the study, not a universal ICH age/risk table. Plan for consent if the participant reaches legal consent age during the trial. Likewise, reassess consent when someone enrolled through a representative gains capacity.
Paper or electronic documentation and remote discussions can be appropriate. Confirm identity, opportunity for questions, privacy, access to the materials and a copy of the signed and dated form. Personally executed electronic dates and signatures can be valid; a handwritten date is not the only acceptable format. Do not use electronic convenience to bypass comprehension or the approved consent process.
Regulatory Re-Consent Triggers
Informed consent is never a closed event. Whenever trial conditions change, investigators must determine whether active participants must be re-consented:
Re-Consent Trigger Underlying Rationale Required Action & Timeline
Protocol Amendments New procedures, increased blood draw volumes, modified visit schedules, or changes to treatment dosage. IRB approves revised ICF; active participants re-consent according to the approved implementation plan, before affected procedures.
New Safety Information Updated Investigator's Brochure, newly identified adverse drug reactions, or regulatory black-box warnings. Communicate relevant new information promptly; obtain applicable approval for revised materials and document updated consent under the reviewed implementation process.
Minor Reaching Age of Majority Pediatric participant turns 18 (or jurisdictional legal adult age) while active in the study. the appropriate consent process should be implemented under applicable requirements; subject must be re-consented as an autonomous adult using the adult ICF before continued activities as required by the approved process.
Cognitive Capacity Recovery Participant who was enrolled via LAR (e.g., comatose stroke patient) regains full decision-making capacity. the applicable consent/representation arrangement should be reassessed; participant must be formally consented using the standard ICF to continue participation.
Study Duration Extension Significant extension of trial follow-up period altering participant commitment. Revised ICF reflecting extended timeline approved by IRB and signed by participants.
CRA Source Data Verification (SDV) for Informed Consent
Consent is a critical process. The CRA verifies it according to the justified monitoring plan; ICH does not prescribe a universal 100% SDV rate. The CRA audits against the 5-Point Consent Verification Protocol :
Warning
Consent Must Precede All Protocol Procedures: Under ICH E6(R3), under the standard consent process, consent should be obtained and documented before trial participation and applicable research procedures. This includes protocol-mandated screening lab panels, diagnostic imaging, and especially washout periods where prescribed standard-of-care medications are discontinued. Taking a patient off an antihypertensive drug to prepare for a screening visit without a signed consent form is a major GCP violation that severely compromises subject safety.
Tip
CRA Red Flag Detection: When auditing consent forms, beware of "convenience dating" where the study coordinator writes the date next to the participant's signature. Both FDA investigators and GCP auditors scrutinize handwriting: if the date beside the participant's signature matches the coordinator's handwriting style, it is cited as an audit finding. Participants should personally execute the required signature and date using the approved paper or electronic process.
Standard chronology and prospectively reviewed exceptions
Compare actual consent timing with the first research activity, including a protocol-directed medication change, rather than checking only whether the dates match. A routine clinical test performed for care before research involvement is a different situation from a new research screening procedure. Establish the purpose and authorised process from evidence.
E6(R3) recognises carefully defined emergency circumstances where prior participant or representative consent is not possible. These require the appropriate prospectively reviewed protocol and safeguards under applicable requirements. An investigator cannot create a blanket exception merely because a patient presents urgently. Verify the approved process and subsequent information/consent requirements rather than applying either an unrestricted emergency waiver or an unexplained absolute rule.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , WMA Declaration of Helsinki, 2024 , ICH E11(R1) .